Drug Type Small molecule drug |
Synonyms Rubraca, rucaparib, Rucaparib phosphate + [9] |
Target |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors), PARP3 inhibitors(Poly (ADP-Ribose) Polymerase 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (19 Dec 2016), |
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US) |
Molecular FormulaC29H34FN3O5S |
InChIKeyINBJJAFXHQQSRW-STOWLHSFSA-N |
CAS Registry1859053-21-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Rucaparib Camsylate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fallopian Tube Carcinoma | EU | 30 Nov 2023 | |
Fallopian Tube Carcinoma | IS | 30 Nov 2023 | |
Fallopian Tube Carcinoma | LI | 30 Nov 2023 | |
Fallopian Tube Carcinoma | NO | 30 Nov 2023 | |
Ovarian Epithelial Carcinoma | EU | 30 Nov 2023 | |
Ovarian Epithelial Carcinoma | IS | 30 Nov 2023 | |
Ovarian Epithelial Carcinoma | LI | 30 Nov 2023 | |
Ovarian Epithelial Carcinoma | NO | 30 Nov 2023 | |
Primary peritoneal carcinoma | EU | 30 Nov 2023 | |
Primary peritoneal carcinoma | IS | 30 Nov 2023 | |
Primary peritoneal carcinoma | LI | 30 Nov 2023 | |
Primary peritoneal carcinoma | NO | 30 Nov 2023 | |
BRCA Mutation Castration-Resistant Prostate Cancer | US | 15 May 2020 | |
Platinum-sensitive epithelial ovarian cancer | EU | 23 May 2018 | |
Platinum-sensitive epithelial ovarian cancer | IS | 23 May 2018 | |
Platinum-sensitive epithelial ovarian cancer | LI | 23 May 2018 | |
Platinum-sensitive epithelial ovarian cancer | NO | 23 May 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | EU | 23 May 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | IS | 23 May 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | LI | 23 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Clear Cell Adenocarcinoma | Phase 3 | DE | 08 Jun 2020 | |
Metastatic castration-resistant prostate cancer | Phase 3 | US | 13 Jun 2017 | |
Metastatic castration-resistant prostate cancer | Phase 3 | AU | 13 Jun 2017 | |
Metastatic castration-resistant prostate cancer | Phase 3 | BE | 13 Jun 2017 | |
Metastatic castration-resistant prostate cancer | Phase 3 | CA | 13 Jun 2017 | |
Metastatic castration-resistant prostate cancer | Phase 3 | DK | 13 Jun 2017 |
Phase 2 | 135 | (Arm A: Cisplatin Monotherapy) | yjweaxudqy(lnjbzmlqqn) = ykghhlacfc fdvzvwlbdk (kfkxyvqxcv, tfkikwcxhs - wtalopnbrt) View more | - | 19 Sep 2024 | ||
yjweaxudqy(lnjbzmlqqn) = lduoyctokv fdvzvwlbdk (kfkxyvqxcv, zdtqjktjss - krmxykeedj) View more | |||||||
Phase 2 | Non-Small Cell Lung Cancer HRDsig+ | BRCA1/2 biallelic alterations | 59 | ojeirsvakw(vnzgwsvetr): HR = 0.5 (95% CI, 0.27 - 0.95), P-Value = 0.033 View more | Positive | 14 Sep 2024 | ||
Placebo | |||||||
Phase 2 | 32 | usdcbadnww(lhwoltecxt) = dzamxutnic sqfyxtixxm (ffozbaupda, ydtcfxseco - kjheynlrac) View more | - | 21 Aug 2024 | |||
Phase 2 | 79 | (Active Ingredient) | pcmntrxbvx(ynzetlbceg) = rhkoakydai txlcukfbbe (xmsjadcgcp, qfysojiqwf - unxbdlnrwz) View more | - | 01 Jul 2024 | ||
Placebo Oral Tablet (Placebo) | pcmntrxbvx(ynzetlbceg) = aoahvpvcwl txlcukfbbe (xmsjadcgcp, ijcvkamcav - ydjctujlhd) View more | ||||||
Phase 3 | Ovarian Cancer First line | 538 | (Overall) | ydkglacung(jlkqvxziri) = oqgqqkxzwy sobeehowed (vkydlwxidn ) View more | Positive | 21 Jun 2024 | |
Placebo (Overall) | ydkglacung(jlkqvxziri) = negksbwrcc sobeehowed (vkydlwxidn ) View more | ||||||
Phase 3 | Ovarian Cancer Maintenance | - | mkdcbygpdl(dvupzholtv) = 28.7% vs 0% gdhiekpkjj (dujfxguryo ) View more | Positive | 24 May 2024 | ||
Placebo | |||||||
Phase 3 | 34 | emqniwyurt(wbinnmmkcy) = tvjvhusznn lwcefwruax (clgneuzzsp, xwrgnckxga - rswtddvpqi) View more | - | 07 May 2024 | |||
Phase 2 | 7 | wvyrfhzeom(drvxzlhtxe) = ydejftrvvq ypxfqchogt (ddcqwdtdfk, sqpzpmugjl - nhtreyliyk) View more | - | 13 Mar 2024 | |||
Phase 3 | Ovarian Cancer Maintenance | First line | 538 | twlibieklr(lhbjryvyai) = cypkpoveji owyhozmfcq (avhpsjxpol ) View more | Positive | 10 Mar 2024 | ||
Placebo | twlibieklr(lhbjryvyai) = tbwrvzoeci owyhozmfcq (avhpsjxpol ) View more | ||||||
NCT03533946 (Pubmed) Manual | Phase 2 | Prostatic Cancer BRCA2 Mutation | Homologous Recombination Deficiency Positive | BRCA1 | 7 | cijfdkkfwz(ugpuekfanb) = qptujabqyg xieisaidab (hdvnenguzy, 0 - 85.11) View more | Positive | 07 Mar 2024 |